More about the safety of tigecycline for the treatment of infectious diseases: The role of superinfection rates

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 1048-1049

  Martín Gandul, Cecilia ^a,b,c   García Cabrera, Emilio ^a,b,c   Castillo Ojeda, Esperanza ^d   Jiménez Mejías, Manuel E ^a,b,c,d  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

^c Spanish Network for Research in Infectious Diseases ^*  (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Glycylcyclines; Multidrug resistant; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COLISTIN; METICILLIN; PENICILLIN G; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; INFECTION; LETTER; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; PATHOGENESIS; SKIN AND SKIN STRUCTURE INFECTION; SKIN INFECTION; SUPERINFECTION; TREATMENT FAILURE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MINOCYCLINE; SUPERINFECTION; YOUNG ADULT;

EID: 84858673076     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr556     Document Type: Letter

References (7)

1. FDA. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (17 November 2011, date last accessed).
2. Tasina E, Haidich AB, Kokkali S et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-44.
3. García-Cabrera E, Jiménez-Mejías ME, Gil Navarro MV et al. Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis 2010; 29: 867-71.
4. Yahav D, Lador A, Paul M et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-71.
5. Cooreman S, Jeurissen A. Comment on: Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother 2011; 66: 1197-8.
6. Parkins MD, Elborn JS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management-authors' response. J Antimicrob Chemother 2011; 66: 1198-9.
7. Curcio D. Tigecycline for severe infections: the gap between the warning and the necessity. J Antimicrob Chemother 2011; 66: 454-6.